VII. Management of nodular lymphocyte-predominant Hodgkin lymphoma

Hematological Oncology

Volumn 31, Issue SUPPL 2, 2013, Pages 47-50

  Eichenauer, Dennis A ^a   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Chemotherapy; Immunotherapy; Nodular lymphocyte predominant Hodgkin lymphoma; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CD15 ANTIGEN; CD20 ANTIGEN; CD30 ANTIGEN; CD45 ANTIGEN; EPITHELIAL MEMBRANE ANTIGEN; IBRUTINIB; OFATUMUMAB; RITUXIMAB;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLASSICAL HODGKIN LYMPHOMA; DRUG MEGADOSE; HUMAN; MALIGNANT TRANSFORMATION; MANTLE CELL LYMPHOMA; MULTIMODALITY CANCER THERAPY; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION SICKNESS; RECURRENT CANCER; TREATMENT OUTCOME;

ANTIGENS, SURFACE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HODGKIN DISEASE; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTES; NEOPLASM STAGING; RECURRENCE;

EID: 84879332660     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2067     Document Type: Article

References (16)

1. Eichenauer DA, Engert A, Dreyling M. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011 Sep; 22(Suppl 6): vi55-8.
2. Nogova L, Rudiger T, Engert A. Biology, clinical course and management of nodular lymphocyte-predominant Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2006; 266-72.
3. Nogova L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2008 Jan 20; 26(3): 434-9.
4. Nogova L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol. 2005 Oct; 16(10): 1683-7.
5. Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol. 2010 Jan 1; 28(1): 136-41.
6. Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2011 Oct 20; 118(16): 4363-5.
7. Savage KJ, Skinnider B, Al-Mansour M, Sehn LH, Gascoyne RD, Connors JM. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood. 2011 Oct 27; 118(17): 4585-90.
8. Fanale MA, Lai C-M, McLaughlin P, et al. Outcomes of nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP. ASH Annual Meeting Abstracts. November 19, 2010; 116(21): 2812.
9. Biasoli I, Stamatoullas A, Meignin V, et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer. 2010 Feb 1; 116(3): 631-9.
10. Al-Mansour M, Connors JM, Gascoyne RD, Skinnider B, Savage KJ. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol. 2010 Feb 10; 28(5): 793-9.
11. Bierman P, Naushad H, Loberiza F, et al. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) for lymphocyte predominant Hodgkin's disease. ASH Annual Meeting Abstracts. November 16, 2006; 108(11): 3061.
12. Jackson C, Sirohi B, Cunningham D, Horwich A, Thomas K, Wotherspoon A. Lymphocyte-predominant Hodgkin lymphoma-clinical features and treatment outcomes from a 30-year experience. Ann Oncol. 2010 Oct; 21(10): 2061-8.
13. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003 Jun 1; 101(11): 4285-9.
14. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008 Jan 1; 111(1): 109-11.
15. Haas RL, Girinsky T, Aleman BM, Henry-Amar M, de Boer JP, de Jong D. Low-dose involved-field radiotherapy as alternative treatment of nodular lymphocyte predominance Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2009 Jul 15; 74(4): 1199-202.
16. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013 Jan 1; 31(1): 88-94.